Goldman Sachs analyst Corinne Johnson has maintained their bullish stance on GERN stock, giving a Buy rating on September 19. Corinne Johnson’s rating is based on the recent advancement in
Goldman Sachs analyst Corinne Johnson has maintained their bullish stance on GERN stock, giving a Buy rating on September 19. Corinne Johnson’s rating is based on the recent advancement in
Goldman Sachs analyst Corinne Johnson reiterated a Buy rating on Geron (GERN – Research Report) today. The company’s shares closed yesterday at $4.60. Johnson covers the Healthcare sector, focusing on
Geron Corporation announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Ziegler will spearhead Geron’s global commercial strategy
הפירמה אופטימית לגבי Geron לשנת 2025 משום שהיא מצפה ש-Rytelo יהיה מאוד מוצלח בטיפול בסוג פחות מסוכן של הפרעת מח עצם הנקראת תסמונת מיאלודיספלסטית בסיכון נמוך. הם גם חוזים שעד
Leerink analyst Faisal Khurshid initiated coverage of Geron with an Outperform rating and $7 price target, and named it a Top Pick in the Emerging Immunology sector. The firm likes